$0.60 EPS Expected for Cantel Medical Corp. (CMD)

May 17, 2018 - By James Guidry

Analysts expect Cantel Medical Corp. (NYSE:CMD) to report $0.60 EPS on May, 31 before the open.They anticipate $0.09 EPS change or 17.65 % from last quarter’s $0.51 EPS. CMD’s profit would be $25.03 million giving it 53.14 P/E if the $0.60 EPS is correct. After having $0.59 EPS previously, Cantel Medical Corp.’s analysts see 1.69 % EPS growth. The stock increased 0.05% or $0.06 during the last trading session, reaching $127.54. About 76,946 shares traded. Cantel Medical Corp. (NYSE:CMD) has risen 41.41% since May 17, 2017 and is uptrending. It has outperformed by 29.86% the S&P500.

Cantel Medical Corp. provides infection prevention services and products for the healthcare market worldwide. The company has market cap of $5.32 billion. The firm operates through four divisions: Endoscopy, Water Purification and Filtration, Healthcare Disposables, and Dialysis. It has a 59.16 P/E ratio. The Endoscopy segment offers automated endoscope reprocessing systems; detergents; leak testing and manual cleaning products; storage cabinets; transport systems; mobile medical carts; endoscope process tracking products; other consumables, accessories, and supplies for use in disinfect rigid and flexible endoscopes, and other instrumentation; cleaning and disinfecting reusable components used in gastrointestinal endoscopy procedures; and technical maintenance services.

More news for Cantel Medical Corp. (NYSE:CMD) were recently published by: Bizjournals.com, which released: “Cantel Medical leases Sleep Number’s former headquarters” on May 17, 2018. Benzinga.com‘s article titled: “Jim Cramer Weighs In On Align Technology, Berkshire Hathaway, Symantec And More” and published on May 15, 2018 is yet another important article.

Cantel Medical Corp. (NYSE:CMD) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: